Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBA
What they do
Novocure manufactures the Optune system, which delivers Tumor Treating Fields to disrupt cancer cell division. The wearable therapy is prescribed by oncologists to treat patients diagnosed with glioblastoma and malignant pleural mesothelioma.
The record
- Vertical
- Medical Devices
- Sub-segment
- Cancer therapy systems
- Product type
- Device
- Stage
- Public
- Headquarters
- Root, Switzerland
- Region
- Europe
- Founded
- 2000
- Total funding
- $100M raised
Notable investors: Johnson & Johnson Development Corporation, Pfizer, Index Ventures.
Also in Medical Devices
Related on The Signal
Dr. Dereck Mush, MD, MBA
Bioelectronic Oncology: The Strategic Science of Coherence Neuro's $45M Brain Cancer Bet
Dr. Dereck Mush, MD, MBA
CAR-T therapy moves beyond cancer, and autoimmune disease becomes the next proving ground
Dr. Dereck Mush, MD, MBA
The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis
Dr. Dereck Mush, MD, MBA